Please assess the completion status of the following clinical trial:

Trial Title: Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with alopecia areata, patchy type (max 3 patches not exceeding 50% of the scalp surface area) of more than 2 months duration.~* Age: 12 years and above~Exclusion Criteria:~* Age: Less than 12 years old.~* Affection of more than 50% of the scalp area~* Diagnosis or history of local dermatological disease in the scalp apart from AA such as eczema, seborrheic dermatitis, psoriasis,..~* Any present / past history of dermatological disease with a potential for koebnerization such as psoriasis, vitiligo.~* Diagnosis or history of any contraindication to receiving phototherapy such as malignancy, systemic lupus~* Dermoscopic evaluation revealing absence of any signs of presence of hair follicles.~* Any psychiatric illness or psychological state impairing future compliance or influencing expectations of the patient.~* Patients with AA totalis or Ophiasis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phototherapeutic (Type: EXPERIMENTAL): 0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions.
- Conventional therapy (Type: ACTIVE_COMPARATOR): One monthly injections of intralesional potent corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).